Format

Send to

Choose Destination
Epilepsy Behav Rep. 2019 Jun 23;12:100326. doi: 10.1016/j.ebr.2019.100326. eCollection 2019.

Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis.

Author information

1
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
2
Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, United States of America.

Abstract

Purpose:

Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAr encephalitis) is an auto-immune disorder associated with the production of antibodies against NR1 and NR2 sub units of the NMDA receptor. Seizures in this population are reported in up to 50% of cases with status epilepticus being reported in 25% of cases, refractory status epilepticus in 13.8% of cases and super-refractory status epilepticus in 10.2% of cases. Treatment of refractory epileptic activity in this population is not uniform and heterogeneous.

Methods:

We present three cases of super refractory status epilepticus in patients with anti-NMDAr encephalitis treated successfully with ketamine, a noncompetitive NMDA receptor antagonist. All patients had failed to improve clinically on multiple anti-convulsants and immunotherapy prior to initiation of ketamine therapy.

Results:

In all three cases, administration of a load followed by maintenance infusion (0.05 mg/kg/min infusion) of ketamine yielded clinical and/or electrographic seizure cessation in less than 48 h. Patients were treated for a heterogeneous duration although ultimately, epilepsy outcomes were favorable from a seizure freedom standpoint. Earlier treatments with ketamine were associated with better epilepsy outcomes in this case series.

Conclusions:

Ketamine may be a useful adjunct treatment in super-refractory status epilepticus in patients with NMDAr encephalitis.

KEYWORDS:

Encephalitis; Epilepsy; Ketamine; NMDA; Refractory status epilepticus

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center